Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,826 across all filing types
Latest filing 2021-04-16 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司九届七次董事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed by the board of directors of 哈药集团股份有限公司 regarding adjustments and approvals related to the 2021 stock option and restricted stock incentive plan. It includes voting results and details about the stock option grants but does not contain comprehensive financial statements or detailed financial performance data. The document is a formal announcement of board decisions rather than a full management report or financial report. It fits best under Board/Management Information (MANG) as it relates to board resolutions and management decisions on stock incentives.
2021-04-16 Chinese
哈药集团股份有限公司关于调整2021年股票期权与限制性股票激励计划首次授予激励对象名单及授予权益数量的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding adjustments to the 2021 stock option and restricted stock incentive plan, including changes to the list of incentive recipients and the number of granted rights. It details board and supervisory approvals, legal and financial advisor opinions, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial performance data but is a formal announcement of changes related to stock incentives. It is not a full annual or interim report, audit report, or earnings release. It is also not a proxy solicitation or voting results announcement. Given the nature of the content—an official announcement about stock option and restricted stock incentive plan adjustments—the most appropriate classification is a Regulatory Filing (RNS), as it does not fit other more specific categories and is a formal regulatory disclosure.
2021-04-16 Chinese
哈药集团股份有限公司2021年股票期权与限制性股票激励计划首次授予部分激励对象名单（授予日）
Capital/Financing Update Classification · 95% confidence The document is titled as a list of recipients for a 2021 stock option and restricted stock incentive plan from 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It details the allocation of stock options and restricted stocks to various executives and core employees, including their positions and the number of shares/options granted. The document includes tables with specific allocation data and notes on the plan's limits and exclusions. There is no indication that this is a full financial report, earnings release, or regulatory filing. Instead, it is an announcement related to stock incentives, which falls under capital or financing activities concerning equity compensation plans. Given the content focuses on stock option and restricted stock grants, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4202 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2021-04-16 Chinese
哈药集团股份有限公司独立董事关于公司九届七次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the company's board meeting, specifically regarding adjustments and approvals related to the 2021 stock option and restricted stock incentive plan. It references compliance with company law, securities law, and stock exchange rules, and discusses governance and approval procedures. The document is not a full financial report, earnings release, or regulatory filing but rather a formal opinion related to board decisions on stock incentives. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is short and focused on board-related matters, not a full report or announcement of a report publication.
2021-04-16 Chinese
哈药集团股份有限公司九届五次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of 哈药集团股份有限公司 regarding resolutions on adjustments and grants related to the 2021 stock option and restricted stock incentive plan. It details voting results, compliance with relevant laws and regulations, and specifics about the stock option and restricted stock grants. The document is an official announcement of decisions made by the supervisory board rather than a full report or financial statement. It does not contain comprehensive financial data or detailed financial analysis, nor is it a transcript, audit report, or regulatory filing of a different nature. The content fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement about corporate governance and stock incentive plan adjustments without being a full management or annual report or a proxy solicitation. The document length is short (1931 characters), and it is a formal announcement of resolutions, not a report publication announcement or a detailed report itself.
2021-04-16 Chinese
哈药集团股份有限公司关于向激励对象首次授予股票期权与限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial grant of stock options and restricted stocks to incentive recipients by 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It includes specifics about the grant date, quantities, conditions, performance targets, and approvals by the board and supervisory committees. The document is a formal announcement of a stock-based incentive plan, including legal and financial advisor opinions, but it is not a financial report, earnings release, or management discussion. It is not a proxy solicitation or voting result announcement either. The content fits the category of a Capital/Financing Update (CAP) because it relates to the issuance of stock options and restricted shares as part of the company's capital incentive plan. The document length is substantial and contains detailed information about the stock option and restricted stock grant, which is typical for a financing update rather than a simple announcement or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2021-04-16 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.